Synaptogenix Total Liabilities 2020-2025 | TAOX
Synaptogenix total liabilities from 2020 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Synaptogenix Annual Total Liabilities
(Millions of US $) |
| 2024 |
$11 |
| 2023 |
$6 |
| 2022 |
$3 |
| 2021 |
$2 |
| 2020 |
$2 |
| 2019 |
$0 |
Synaptogenix Quarterly Total Liabilities
(Millions of US $) |
| 2025-03-31 |
$9 |
| 2024-12-31 |
$11 |
| 2024-09-30 |
$10 |
| 2024-06-30 |
$10 |
| 2024-03-31 |
$7 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$7 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$3 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
|
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2019-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.012B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
